Moderna, Inc. — Director's Dealing 2018

Dec 7, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07

Reporting Person: NABEL ELIZABETH G (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	30665	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series G Preferred Stock	$		Common Stock (13679)		Direct
Stock Option (Right to Buy)	$10.90	2026-02-23	Common Stock (12376)		Direct
Stock Option (Right to Buy)	$19.15	2026-08-10	Common Stock (10948)		Direct
Stock Option (Right to Buy)	$19.15	2026-08-10	Common Stock (8376)		Direct
Stock Option (Right to Buy)	$12.21	2027-02-23	Common Stock (42201)		Direct
Stock Option (Right to Buy)	$14.22	2028-02-28	Common Stock (40307)		Direct

Footnotes

F1: Each share of Series G Preferred Stock is convertible into shares of the Issuer's common stock, $0.0001 par value per share ("Common Stock") based on an applicable conversion ratio of 0.45872. Upon the closing of the Issuer's initial public offering, all shares of Series G Preferred Stock will convert into shares of Common Stock of the Issuer. The Series G Preferred Stock has no expiration date.

F2: This option is fully vested and exercisable.

F3: This option will become fully vested and exercisable on February 28, 2019.